干旱区生态环境知识资源中心(Arid): Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes

Arid

DOI	10.1016/j.pathol.2020.09.004
	Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes
	Takahara, Taishi; Murase, Yota; Tsuzuki, Toyonori
通讯作者	Tsuzuki, T (corresponding author), Aichi Med Univ Hosp, Dept Surg Pathol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
来源期刊	PATHOLOGY
ISSN	0031-3025
EISSN	1465-3931
出版年	2021
卷号	53 期号:1 页码:56-66
英文摘要	Although urothelial carcinoma (UC) has been recognised as a homogenous disease entity until recently, it exhibits widely diverse histological variants. Recent studies have revealed that some histological variants may serve as markers of very high risk for advanced cancers and poor prognoses. Certain histological variants can generate a pathological T stage, which may result in unnecessary surgery. Though platinum based chemotherapy is the standard treatment, the use of immune checkpoint inhibitors (ICIs) for UC treatment has become a major trend in oncology. UCs showing specific histological variants have responded exceptionally well to chemotherapy and ICIs. Currently, molecular studies base molecular classification on gene expression profile signatures in order to make diagnoses or predict responses to chemotherapies and ICIs. Notably, some histological variants correlate with specific molecular subtypes. The usefulness of immunophenotyping for classification purposes was recognised only recently. Immunophenotypes are classified into three categories according to lymphocyte distribution in or around the cancer cell nest: desert, excluded, and inflamed. This immunophenotyping has been increasingly shown to be of value in predicting the response to ICIs. This review describes the morphological characteristics of histological variants as well as the advantages and limitations in determining them, with particular reference to clinical benefits. Subsequently, we describe the concept of molecular classification and immunophenotypes, and their morphological features, which are easily interpreted and amenable to daily practice via hematoxylin and eosin staining. We also consider the clinical advantages, limitations, and issues encountered while using these in routine clinical practice.
英文关键词	Urothelial carcinoma variant histology molecular subtype immunophenotype prognosis chemosensitivity immune checkpoint inhibitor
类型	Article
语种	英语
收录类别	SCI-E
WOS记录号	WOS:000605365200007
WOS关键词	TRANSITIONAL-CELL-CARCINOMA ; INVASIVE BLADDER-CANCER ; LYMPHOEPITHELIOMA-LIKE CARCINOMA ; URINARY-BLADDER ; RADICAL CYSTECTOMY ; NEOADJUVANT CHEMOTHERAPY ; GLANDULAR DIFFERENTIATION ; SQUAMOUS DIFFERENTIATION ; MICROPAPILLARY VARIANT ; CLINICAL-SIGNIFICANCE
WOS类目	Pathology
WOS研究方向	Pathology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/348088
作者单位	[Takahara, Taishi; Murase, Yota; Tsuzuki, Toyonori] Aichi Med Univ Hosp, Dept Surg Pathol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan
推荐引用方式 GB/T 7714	Takahara, Taishi,Murase, Yota,Tsuzuki, Toyonori. Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes[J],2021,53(1):56-66.
APA	Takahara, Taishi,Murase, Yota,&Tsuzuki, Toyonori.(2021).Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes.PATHOLOGY,53(1),56-66.
MLA	Takahara, Taishi,et al."Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes".PATHOLOGY 53.1(2021):56-66.